CytomX Therapeutics, Inc. Aktie News

CytomX (NASDAQ: CTMX ) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report. The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024.

- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed tow...

- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors.

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -

CytomX Therapeutics (NASDAQ: CTMX ) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report. The CytomX Therapeutics earnings report notes that the company spent most of 2023 cutting costs to continue operations.

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Joe Catanzaro - Piper Sandler Malcolm Kuno - JPMorgan Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeut...